<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02015351</url>
  </required_header>
  <id_info>
    <org_study_id>Brazilian VKH Study Group</org_study_id>
    <nct_id>NCT02015351</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study</brief_title>
  <official_title>Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease - A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy of monthly intravitreal anti-vascular endothelial growth factor (VEGF) associated to
      systemic immunosuppression in patients with Vogt-Koyanagi-Harada Disease and choroidal
      neovascularization. Minimum follow-up 12 months. Endpoints: 6 and 12 months of follow-up.
      Outcome measures: improvement of VA, decrease in central foveal thickness as measured by
      Optical Coherence Tomography (OCT) and absence of intra/subretinal fluid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Choroidal neovascularization (CNV) in Vogt-Koyanagi-Harada (VKH) disease is associated with
      poor visual prognosis. Several treatments have been suggested, though there is still no
      standard therapy. CNV diagnosis will be based on fundus biomicroscopy (presence of serous
      retinal detachment with or without retinal hemorrhages), fluorescein angiography (FA)
      (presence of early phase hyperfluorescence with late phase leakage) and OCT findings
      (hyperreflective lesion related to a CNV complex with serous foveal detachment or
      intraretinal fluid with increased foveal thickness). Inflammation will be considered active
      if anterior chamber cells or optic disc leakage in FA is observed. Each patient will undergo
      a complete clinical exam, including best corrected visual acuity (VA) (Snellen charts). Once
      active CNV is identified, a loading dose of 3 injections of IV bevacizumab will be proceeded
      monthly and systemic immunosuppression will be introduced or intensified. After the first 3
      injections, the patient will be clinically examined and OCT will be proceeded monthly. The
      persistence of intra/subretinal fluid in the OCT will indicate one more IV bevacizumab
      injection. Immunosuppression status evaluation will be done at 3, 6, 9 and 12 months of
      follow up and intensification will be done if inflammatory signs or persistence of
      intraretinal fluid is observed. Presence of intra/subretinal fluid and manual measurement of
      retina central foveal thickness (CFT) will be proceeded in horizontal scan by the same
      examiner.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity change</measure>
    <time_frame>6 months</time_frame>
    <description>Visual Acuity will be measured using Snellen charts with best refraction by the same examiner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in central foveal thickness</measure>
    <time_frame>6 months</time_frame>
    <description>Central foveal thickness will be measured manually using the caliper by the same examiner. Measurements will be proceeded from the Bruch`s membrane till the internal limiting membrane and comparison with previous measurement will be done.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence or absence of intra/subretinal fluid in OCT</measure>
    <time_frame>6 months</time_frame>
    <description>OCT will be analyzed at 6 and 12 months for the presence of intra or subretinal fluid.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity change</measure>
    <time_frame>12 months</time_frame>
    <description>Visual Acuity will be measured using Snellen charts with best refraction by the same examiner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Central Foveal Thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Central foveal thickness will be measured manually using the caliper by the same examiner. Measurements will be proceeded from the Bruch`s membrane till the internal limiting membrane and comparison with previous measurement will be done.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or Absence of Intra/Subretinal fluid in OCT</measure>
    <time_frame>12 months</time_frame>
    <description>OCT will be analyzed at 6 and 12 months for the presence of intra or subretinal fluid.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Anti-VEGF and Immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab: Dosage 1.25mg/0.05ml; Frequency monthly injections; Duration at least 3 months.
Immunosuppression: cyclosporine and/or azathioprine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.</description>
    <arm_group_label>Anti-VEGF and Immunosuppression</arm_group_label>
    <other_name>Bevacizumab (Avastin;Genentech Inc,USA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with Vogt-Koyanagi-Harada disease based on Revised Diagnostic
             Criteria presented by the International Committee on VKH disease in 2001;

          2. Presence of choroidal neovascularization identified by fundus biomicroscopy,
             fluorescein angiography and OCT.

        Exclusion Criteria:

          -  Media opacities precluding posterior segment exam, ametropia over 5 dioptries,
             glaucoma (defined as a disease with characteristic damage at the optic nerve or
             characteristic visual field defect with compatible nerve fiber layer lesion), Age
             related Macular degeneration, impossibility to increase immunosuppression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce H Yamamoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo School of Medicine Ophthalmology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Viviane M Sakata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clínicas- University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Perentes Y, Van Tran T, Sickenberg M, Herbort CP. Subretinal neovascular membranes complicating uveitis: frequency, treatments, and visual outcome. Ocul Immunol Inflamm. 2005 Apr-Jun;13(2-3):219-24.</citation>
    <PMID>16019682</PMID>
  </results_reference>
  <results_reference>
    <citation>Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina. 2011 May;31(5):871-9. doi: 10.1097/IAE.0b013e3182003ca8.</citation>
    <PMID>21358461</PMID>
  </results_reference>
  <results_reference>
    <citation>Adán A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina. 2007 Nov-Dec;27(9):1180-6.</citation>
    <PMID>18046222</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu L, Evans T, Saravia M, Schlaen A, Couto C. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol. 2009 Jan;53(1):57-60. doi: 10.1007/s10384-008-0600-4. Epub 2009 Jan 30.</citation>
    <PMID>19184312</PMID>
  </results_reference>
  <results_reference>
    <citation>Kolomeyer AM, Roy MS, Chu DS. The use of intravitreal ranibizumab for choroidal neovascularization associated with vogt-koyanagi-harada syndrome. Case Rep Med. 2011;2011:747648. doi: 10.1155/2011/747648. Epub 2011 Aug 3.</citation>
    <PMID>21826150</PMID>
  </results_reference>
  <results_reference>
    <citation>Tran TH, Fardeau C, Terrada C, Ducos De Lahitte G, Bodaghi B, Lehoang P. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol. 2008 Dec;246(12):1685-92. doi: 10.1007/s00417-008-0906-4. Epub 2008 Aug 6.</citation>
    <PMID>18682970</PMID>
  </results_reference>
  <results_reference>
    <citation>Nowilaty SR, Bouhaimed M; Photodynamic Therapy Study Group. Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2006 Aug;90(8):982-6. Epub 2006 May 10.</citation>
    <PMID>16687455</PMID>
  </results_reference>
  <results_reference>
    <citation>Mansour AM, Arevalo JF, Ziemssen F, Mehio-Sibai A, Mackensen F, Adan A, Chan WM, Ness T, Banker AS, Dodwell D, Chau Tran TH, Fardeau C, Lehoang P, Mahendradas P, Berrocal M, Tabbarah Z, Hrisomalos N, Hrisomalos F, Al-Salem K, Guthoff R. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol. 2009 Aug;148(2):310-316.e2. doi: 10.1016/j.ajo.2009.03.023. Epub 2009 May 9.</citation>
    <PMID>19427992</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Joyce Hisae Yamamoto</investigator_full_name>
    <investigator_title>MD, PhD, Coordinator of the Uveitis Service</investigator_title>
  </responsible_party>
  <keyword>Choroidal neovascularization</keyword>
  <keyword>Vogt Koyanagi Harada Disease</keyword>
  <keyword>Inflammatory choroidal neovascularization</keyword>
  <keyword>Anti-VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Uveomeningoencephalitic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

